Alış
Synthetic Biologics Bullish Momentum
Synthetic Biologics Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol.
A previously completed placebo-controlled Phase 2b clinical trial of 412 patients demonstrated SYN-004 protected the gut microbiome from antibiotic-mediated dysbiosis. Patients receiving SYN-004 also demonstrated significantly better maintenance and recovery of the gut microbiome as well as lower incidences of new colonization by opportunistic and potentially pathogenic microorganisms such as VRE. (Source: prnewswire.com)
Please leave me a message if you want to test the buy and sell indicators that i am using.
A previously completed placebo-controlled Phase 2b clinical trial of 412 patients demonstrated SYN-004 protected the gut microbiome from antibiotic-mediated dysbiosis. Patients receiving SYN-004 also demonstrated significantly better maintenance and recovery of the gut microbiome as well as lower incidences of new colonization by opportunistic and potentially pathogenic microorganisms such as VRE. (Source: prnewswire.com)
Please leave me a message if you want to test the buy and sell indicators that i am using.
Copy my trades: partner.bybit.com/b/best_copy_trading
BUY-SELL INDICATORS: bit.ly/indicatorz
TRADING COURSE: bit.ly/10Xtrading
STOCK OPTIONS SIGNALS: bit.ly/options_signals
BUY-SELL INDICATORS: bit.ly/indicatorz
TRADING COURSE: bit.ly/10Xtrading
STOCK OPTIONS SIGNALS: bit.ly/options_signals
Feragatname
Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, işlem veya diğer türden tavsiye veya tavsiyeler anlamına gelmez ve teşkil etmez. Kullanım Şartları'nda daha fazlasını okuyun.